Physician profile
Aleithe N Alvarez
NPI 1790223154
$1,031.64
in general payments reported to CMS, 2019-2025
25 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.98 · 2022: $102 · 2023: $399 · 2024: $300 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.00 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $117.21 | 2023-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $103.40 | 2024-2025 | Mounjaro, Jardiance |
| Janssen Biotech, INC. | $91.68 | 2023-2024 | Simponi, Simponi Aria, Stelara |
| Novo Nordisk INC | $82.06 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $80.04 | 2022-2023 | |
| Abbott Laboratories | $65.16 | 2021-2024 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $63.15 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals Lp | $51.93 | 2021-2025 | Breztri |
| Glaxosmithkline, LLC. | $45.03 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $44.68 | 2023-2024 | |
| Dexcom, INC. | $40.96 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $24.20 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.34 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.93 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $19.41 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $18.86 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.83 | 2023 | |
| Esperion Therapeutics, INC. | $17.59 | 2021 | |
| Boston Scientific Corporation | $16.96 | 2023 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.60 | 2024 | |
| Medtronic, INC. | $15.62 | 2025 | Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $14.71 | 2024 | Nuedexta |
| Novartis Pharmaceuticals Corporation | $13.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.77 | 2023 | Gattex |
| Pfizer INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleithe Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.